A review of targeted therapies for anemia in patients with lower-risk myelodysplastic syndromes and myelofibrosis that improve transfusion independence and hemoglobin levels.
Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback